Powder: -20°C for 3 years | In solvent: -80°C for 1 year
K201 (JTV-519) 是一种 Ca2+ 依赖性阻滞剂,通过稳定兰尼碱受体来防止缺血性心脏和骨骼肌 (SkM) 中的肌质网异常 Ca(2+) 泄漏。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 385 | 现货 | ||
5 mg | ¥ 783 | 现货 | ||
10 mg | ¥ 1,120 | 现货 | ||
25 mg | ¥ 1,820 | 现货 | ||
50 mg | ¥ 2,690 | 现货 | ||
100 mg | ¥ 3,980 | 现货 | ||
500 mg | ¥ 8,720 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 813 | 现货 |
产品描述 | K201 (JTV-519) is a Ca2+-dependent blocker and prevents abnormal Ca(2+) leak from the sarcoplasmic reticulum in the ischemic heart and skeletal muscle (SkM) by stabilizing the ryanodine receptors. |
体外活性 | In isolated cardiac and SkM SR microsomes, K201 slowed the rate of SR Ca(2+) loading, suggesting potential SERCA block and/or RyR agonism. K201 displayed Ca(2+)-dependent inhibition of SERCA-dependent ATPase activity, which was measured in microsomes incubated with 200, 2, and 0.25 µM Ca(2+) and with the half-maximal K201 inhibitory doses (IC50) estimated at 130, 19, and 9 µM (cardiac muscle) and 104, 13, and 5 µM (SkM SR). K201 (≥5 µM) increased RyR1-mediated Ca(2+) release from SkM microsomes. Maximal K201 doses at 80 µM produced ∼37% of the increase in SkM SR Ca(2+) release observed with the RyR agonist caffeine. K201 (≥5 µM) increased the open probability (Po) of very active ('high-activity') RyR1 of SkM reconstituted into bilayers, but it had no effect on 'low-activity' channels. Likewise, K201 activated cardiac RyR2 under systolic Ca(2+) conditions (∼5 µM; channels at Po ∼0.3) but not under diastolic Ca(2+) conditions (∼100 nM; Po < 0.01)[1]. |
别名 | K-201, JTV 519, JTV-519, K 201 |
分子量 | 461.06 |
分子式 | C25H33ClN2O2S |
CAS No. | 1038410-88-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (54.22 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1689 mL | 10.8446 mL | 21.6892 mL | 54.2229 mL |
5 mM | 0.4338 mL | 2.1689 mL | 4.3378 mL | 10.8446 mL | |
10 mM | 0.2169 mL | 1.0845 mL | 2.1689 mL | 5.4223 mL | |
20 mM | 0.1084 mL | 0.5422 mL | 1.0845 mL | 2.7111 mL | |
50 mM | 0.0434 mL | 0.2169 mL | 0.4338 mL | 1.0845 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
K201 1038410-88-6 Membrane transporter/Ion channel Metabolism Calcium Channel JTV519 K-201 JTV 519 JTV-519 K 201 Inhibitor inhibitor inhibit